Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients

Internal Medicine

Volumn 51, Issue 6, 2012, Pages 553-557

  Gunes, Fahri ^a   Akbal, Erdem ^a   Cakir, Evrim ^a   Akyurek, Omer ^a   Altunbas, Mustafa ^a   Ozbek, Mustafa ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Endothelial dysfunction; Essential hypertension; Visfatin

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; PREHYPERTENSION; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADIPOSITY; AGED; AGING; ALCOHOL DRINKING; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CYTOKINES; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INTRA-ABDOMINAL FAT; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREHYPERTENSION; SMOKING; WAIST CIRCUMFERENCE;

EID: 84858221241     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6609     Document Type: Article

References (22)

1. Samal B, Sun Y, Stearns G, Xie C, Suggs S, Mc Niece I. Cloning and characterization of the cDNA encoding a novel human pre-Bcell colony enhancing factor. Mol Cell Biol 14: 1431-1437, 1994.
2. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916, 2005.
3. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67: 796-800, 2007.
4. Moschen AR, Gerner RR, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. Curr Pharm Des 16: 1913-1920, 2010.
5. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113: 1318-1327, 2004.
6. Park BS, Jin SH, Park JJ, et al. Visfatin induces sickness responses in the brain. PLoS One 6: e15981, 2011.
7. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-1758, 2007.
8. Gupta V, Sachdeva S, Khan AS, Haque SF. Endothelial dysfunction and inflammation in different stages of essential hypertension. Saudi J Kidney Dis Transpl 1: 97-103, 2011.
9. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium dependant vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27, 1990.
10. Zhang ZH, Wei SG, Francis J, Felder RB. Cardiovascular and renal sympathetic activation by blood-borne TNF in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284: R916-R927, 2003.
11. Granger JP. An emerging role for inflammatory cytokines in hypertension. Am J Physiol Heart Circ Physiol 290: H923-H924, 2006.
12. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003.
13. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Associa tion/National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735-2752, 2005.
14. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51: 810-824, 2005.
15. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56: 565-570, 2007.
16. Samara A, Pfister M, Marie B, Visvikis-Siest S. Visfatin, lowgrade inflammation and body mass index (BMI). Clin Endocrinol 69: 568-574, 2008.
17. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56: 1216-1220, 2007.
18. Dogru T, Sonmez A, Tasci I, et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 21: 173-175, 2007.
19. Schutte AE, Huisman HW, Schutte R, et al. Adipokines and cardiometabolic function: How are they interlinked? Regul Pept 164: 133-138, 2010.
20. Romacho T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 52: 2455-2463, 2009.
21. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370-380, 2009.
22. Wang P, Du H, Zhang RY, et al. Circulating and local visfatin/ Nampt/PBEF levels in spontaneously hypertensive rats, strokeprone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 60: 317-324, 2010.